Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IDXX 
IDEXX Laboratories Inc (IDXX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: IDXX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $695.09
1 Year Target Price $695.09
| 3 | Strong Buy |
| 3 | Buy |
| 6 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.57% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 51.29B USD | Price to earnings Ratio 53.47 | 1Y Target Price 695.09 |
Price to earnings Ratio 53.47 | 1Y Target Price 695.09 | ||
Volume (30-day avg) 13 | Beta 1.56 | 52 Weeks Range 356.14 - 688.12 | Updated Date 09/14/2025 |
52 Weeks Range 356.14 - 688.12 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 11.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 24.41% | Operating Margin (TTM) 33.62% |
Management Effectiveness
Return on Assets (TTM) 23.26% | Return on Equity (TTM) 64.87% |
Valuation
Trailing PE 53.47 | Forward PE 45.05 | Enterprise Value 52366886511 | Price to Sales(TTM) 12.7 |
Enterprise Value 52366886511 | Price to Sales(TTM) 12.7 | ||
Enterprise Value to Revenue 12.97 | Enterprise Value to EBITDA 37.42 | Shares Outstanding 80004704 | Shares Floating 79118242 |
Shares Outstanding 80004704 | Shares Floating 79118242 | ||
Percent Insiders 0.68 | Percent Institutions 97.52 |
Upturn AI SWOT
IDEXX Laboratories Inc
Company Overview
History and Background
IDEXX Laboratories Inc. was founded in 1983 and has evolved into a global leader in pet healthcare innovation, serving veterinarians worldwide. Initial focus was on livestock diagnostics, later shifting to companion animals.
Core Business Areas
- CAG Diagnostics: Provides diagnostic products and services for companion animals, including in-clinic instruments, reference laboratory services, and point-of-care diagnostics.
- Water Quality Products: Offers tests and equipment used to measure various parameters in water, used for drinking water and environmental safety.
- Livestock, Poultry and Dairy: Offers products used in veterinary practices for livestock, poultry, and dairy animals.
Leadership and Structure
The CEO is Jonathan Ayers. The company structure is organized by business segments, with global operations and research & development teams.
Top Products and Market Share
Key Offerings
- VetLab Suite: Integrated in-clinic diagnostic instruments and software. Market share in companion animal diagnostics is estimated at ~25%. Competitors: Zoetis (ZTS), Heska (HSKA) (now part of Zoetis), Abaxis (acquired by Zoetis).
- Reference Laboratories: Comprehensive diagnostic testing services offered through a global network of laboratories. Market share is estimated around 25%. Competitors: Antech Diagnostics (Mars Veterinary Health), VCA Antech (acquired by Mars).
- SNAP Tests: Point-of-care diagnostic tests for various diseases in pets. Market share varies depending on the specific test. Competitors: Zoetis, Heska.
Market Dynamics
Industry Overview
The veterinary diagnostics market is growing due to increased pet ownership, rising veterinary care standards, and advancements in diagnostic technology. Aging pet population and increased spending on pet healthcare also contribute to market growth.
Positioning
IDEXX is a market leader in veterinary diagnostics, with a strong brand reputation, innovative products, and a global presence. Their competitive advantage lies in their integrated solutions, extensive reference laboratory network, and commitment to innovation.
Total Addressable Market (TAM)
The global veterinary diagnostics market is projected to reach $8.5 billion by 2024. IDEXX is positioned to capture a significant portion of this TAM through its established market presence and product portfolio.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Extensive global network
- Innovative product portfolio
- Integrated diagnostic solutions
- High customer retention rate
Weaknesses
- Premium pricing strategy can limit market access in some regions
- Reliance on third-party distributors in certain markets
- Exposure to currency fluctuations
Opportunities
- Expanding into emerging markets
- Developing new diagnostic tests and technologies
- Increasing penetration of in-clinic diagnostic solutions
- Leveraging data analytics to improve diagnostic accuracy and efficiency
- Partnerships with veterinary clinics and hospitals
Threats
- Increasing competition from other diagnostic companies
- Price pressures from generic diagnostic products
- Changes in veterinary regulations
- Economic downturns impacting pet ownership and veterinary spending
- Technological disruptions
Competitors and Market Share
Key Competitors
- ZTS
- ANH
- BIO
Competitive Landscape
IDEXX's competitive advantage lies in its integrated solutions and global network. Zoetis is a major competitor with a strong presence in animal health. ANH is also a significant player in veterinary diagnostics. BIO can focus on research and diagnostics for a wide range of industries.
Major Acquisitions
ezyVet
- Year: 2021
- Acquisition Price (USD millions): 620
- Strategic Rationale: Strengthens software and services offerings, integrating practice management software with diagnostics.
Growth Trajectory and Initiatives
Historical Growth: IDEXX has demonstrated strong revenue and earnings growth over the past decade, driven by organic growth and strategic acquisitions.
Future Projections: Analysts project continued revenue and earnings growth for IDEXX, fueled by the expanding veterinary diagnostics market and the company's innovation pipeline.
Recent Initiatives: Recent strategic initiatives include expanding the reference laboratory network, launching new diagnostic tests, and investing in research and development.
Summary
IDEXX Laboratories Inc. is a strong player in the veterinary diagnostics industry, supported by a global network, innovative products, and consistent growth. Its integrated solutions provide a competitive edge, though premium pricing and competition remain potential challenges. The company is well positioned to capitalize on the expanding veterinary healthcare market. They should watch out for economic downturns impacting pet ownership and veterinary spending.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Analyst Reports
- Industry Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IDEXX Laboratories Inc
Exchange NASDAQ | Headquaters Westbrook, ME, United States | ||
IPO Launch date 1991-06-21 | President, CEO & Director Mr. Jonathan J. Mazelsky | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.idexx.com |
Full time employees 11000 | Website https://www.idexx.com | ||
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.